CBD for Dogs: What Current Veterinary Research Can and Cannot Tell Us
Last reviewed · Citation policy
The evidence on CBD for dogs is mixed and still limited. What peer-reviewed research says about safety, efficacy, drug interactions, and quality — and how to opt out of CBD product recommendations.
Published
2022
Updated
Apr 10, 2026
References
6 selected
Pharmacology and botanical classification
CBD (cannabidiol) is one of over a hundred phytocannabinoids identified in Cannabis sativa, and it is pharmacologically distinct from delta-9-tetrahydrocannabinol (THC) in that it does not produce the psychoactive intoxication associated with THC receptor agonism. In the veterinary nutraceutical market, CBD is typically derived from industrial hemp cultivars, which were reclassified under the 2018 Agriculture Improvement Act (Farm Bill) as containing not more than 0.3 percent delta-9 THC on a dry weight basis — the operative legal threshold distinguishing hemp from controlled cannabis.
The primary pharmacological mechanism of interest involves the endocannabinoid system (ECS), a lipid-signaling network shared across mammalian species, comprising CB1 receptors (concentrated in the central nervous system) and CB2 receptors (predominant in peripheral immune tissue). Unlike THC, which acts as a direct partial agonist at CB1 receptors, CBD exhibits a more complex pharmacological profile — functioning as a negative allosteric modulator of CB1, while also interacting with serotonin 5-HT1A receptors and transient receptor potential vanilloid (TRPV1) channels. The downstream pathways by which these receptor interactions might modulate anxiety-related behavior in dogs remain under active investigation.
CBD is not a synonym for hemp
This distinction carries regulatory and clinical significance. Many calming supplements marketed as "hemp" products rely on hemp seed oil or hemp powder, neither of which contains pharmacologically meaningful concentrations of cannabidiol. Products derived from hemp seeds occupy a fundamentally different regulatory classification, present different phytochemical profiles, and carry different levels of clinical relevance for anxiolytic applications relative to CBD-containing extracts derived from hemp inflorescences and leaves. A product that does not specify cannabidiol content in milligrams per serving is likely a hemp-seed derivative rather than a functional CBD formulation — though products labeled "hemp extract," "whole-plant extract," or "THC-removed extract" may still contain cannabinoids and require COA verification to confirm. See the full analysis in the hemp vs. CBD guide.
Key takeaway
CBD is a specific phytocannabinoid with a complex pharmacological profile involving ECS modulation, 5-HT1A receptor interaction, and TRPV1 activity. It is neither equivalent to hemp-seed derivatives nor to THC. Legal hemp is defined as not more than 0.3 percent delta-9 THC by dry weight under the 2018 Farm Bill.
Clinical evidence review: safety and behavioral efficacy
The honest summary of the current literature: short-term tolerability profiles appear reasonable across available pharmacokinetic and safety studies, but behavioral efficacy evidence is considerably thinner, more methodologically variable, and harder to generalize across populations than product marketing suggests.
Safety and tolerability
Generally favorable in short-term studies; hepatic enzyme elevation is a consistent finding.
The 2023 narrative review by Di Salvo and colleagues (PMCID: PMC10347378) concluded that the majority of canine pharmacokinetic and tolerability data derives from four osteoarthritis randomized controlled trials. Dogs generally tolerated oral CBD administration over short dosing periods (typically 2–12 weeks), with the most frequently observed adverse effects being gastrointestinal — principally soft stool and transient appetite reduction. However, multiple studies documented dose-dependent alkaline phosphatase (ALP) elevation, which Di Salvo et al. (2023) identified as a consistent safety finding across studies, suggesting hepatobiliary response warranting longitudinal monitoring. The available safety dataset remains constrained by relatively small cohort sizes (often n<30) and insufficient chronic-exposure duration to establish long-term safety margins.
Behavioral efficacy: overview
Limited and mixed. Three clinical behavioral studies as of the 2023 review; evidence base heterogeneous.
Di Salvo et al. (2023; PMCID: PMC10347378) identified only three clinical studies examining CBD for behavioral outcomes in dogs — one positive, one mixed, one negative — which constitutes an evidence base too small and heterogeneous to support confident directional conclusions. A separate systematic review and meta-analysis (PMCID: PMC10540436), using GRADE methodology for osteoarthritis endpoints, rated the overall certainty of evidence as "very low" due to risk-of-bias concerns, imprecision, and inconsistency. While that assessment concerns a different clinical indication, the methodological quality rating reflects the broader maturity of the canine CBD evidence base.
Hunt et al. 2023: acute separation and car-travel stress
Behavioral QBA measures reached significance; subjective sedation-related measures did not.
Hunt, Flint, Logan, and King (2023; PMCID: PMC9992179) conducted a randomized, placebo-controlled study evaluating a single oral CBD dose in dogs subjected to acute separation and car-travel stressors. Quantitative Behavioral Analysis (QBA) measures — including stress, tension, discomfort, sadness, and whining — did reach statistical significance and showed improvement in the CBD condition. This represents a genuine positive finding within a controlled experimental framework. However, the study authors explicitly cautioned against extrapolating results to CBD products as a broad commercial category, noting that bioavailability, formulation excipients, cannabinoid concentration, and manufacturing quality all introduce variables that a single-product trial cannot account for.
Flint et al. 2025: 4-arm crossover (n=54)
CBD monotherapy failed to reach significance at either dose; only the combination arm did.
Flint, Weller, Hunt, and King (2025; PMCID: PMC12339541) conducted a blinded 4-arm crossover trial enrolling 54 dogs, evaluating placebo, CBD 2 mg/kg, CBD 4 mg/kg, and a combination treat (CBD 2 mg/kg + L-tryptophan + alpha-casozepine) during car-travel stress, with salivary cortisol as the primary neuroendocrine biomarker. CBD alone at 2 mg/kg and at 4 mg/kg did not reach significance. Only the combination arm significantly attenuated salivary cortisol response (p=0.016). The investigators documented high inter-individual pharmacokinetic variability in CBD bioavailability across subjects. The Flint et al. (2025) combination-arm finding is a preliminary signal for multi-ingredient formulations but does not support generalized efficacy claims for CBD as a monotherapy anxiolytic.
Rideout et al. 2025: regulatory and quality context
Narrative review. Addresses product quality and regulatory gaps, not behavioral outcomes.
Rideout, Cook, Whetton, and colleagues (2025; PMCID: PMC11755934) published a review examining the regulatory and quality assurance landscape for CBD products in the veterinary market. This review does not provide behavioral efficacy data and does not permit causal inference about anxiolytic effects. It is contextually relevant because it establishes the quality assurance problem: in the absence of pre-market federal oversight, product potency and purity vary substantially across the commercial CBD pet supplement market, and independent COA verification is the primary accountability mechanism available to practitioners and researchers evaluating specific formulations.
Key takeaway
Short-term tolerability is generally reasonable; hepatic ALP elevation is a consistent finding across studies. Behavioral efficacy evidence as of 2025 includes: one positive QBA behavioral study (Hunt et al., 2023); one 4-arm crossover where CBD monotherapy failed at both tested doses and only a combination arm reached significance (Flint et al., 2025); and a regulatory/quality narrative review that contextualizes the unregulated CBD pet market (Rideout et al., 2025). The behavioral evidence base is insufficient for category-wide efficacy claims.
Drug interactions and contraindications
CBD undergoes extensive hepatic first-pass metabolism, primarily through the cytochrome P450 (CYP450) enzyme superfamily. Di Salvo et al. (2023; PMCID: PMC10347378) identified that CBD primarily inhibits CYP450 — a pharmacokinetic property that gives it the potential to elevate plasma concentrations of co-administered pharmaceuticals cleared through the same metabolic pathways. In clinical practice, this interaction profile represents one of the more consequential safety considerations for dogs receiving concurrent medication.
Hepatic enzyme elevation
Multiple pharmacokinetic studies have documented dose-dependent elevation of serum alkaline phosphatase (ALP) in dogs receiving oral CBD, consistent with hepatic enzyme induction that may indicate subclinical cholestatic stress. While isolated ALP elevation is not inherently pathological, it warrants serial hepatic panel monitoring — particularly in dogs with pre-existing hepatobiliary disease or those concurrently receiving medications that undergo significant hepatic biotransformation.
CYP450-mediated drug interactions
Dogs concurrently prescribed CYP450-metabolized anticonvulsant medications (phenobarbital, zonisamide), nonsteroidal anti-inflammatory drugs (NSAIDs), or any pharmaceutical undergoing hepatic CYP450-mediated clearance are at elevated risk for pharmacokinetic interactions. Note: potassium bromide, another anticonvulsant used in dogs, is excreted unchanged by the kidneys and is not expected to interact via the CYP450 pathway. The drug-drug interaction potential is grounded in well-characterized metabolic pathway competition documented in both human and veterinary pharmacology literature.
Reproductive and developmental exposure
No reproductive toxicology or lactation transfer studies for CBD have been conducted in dogs. Teratogenic potential and neonatal exposure risk are entirely uncharacterized in the species-specific literature. CBD is contraindicated in pregnant or lactating dogs until species-specific safety data become available.
Key takeaway
CBD primarily inhibits CYP450, with the potential to alter plasma concentrations of co-administered medications. Hepatic ALP elevation is a consistent and documented finding. Reproductive safety data are absent for the species.
Regulatory environment and quality assurance
The regulatory environment governing CBD-containing veterinary nutraceuticals remains jurisdictionally fragmented and substantively unsettled, with direct implications for product quality assurance.
FDA position
The FDA has not granted approval, conditional approval, or indexing for any CBD product intended for veterinary use. The agency's Center for Veterinary Medicine (CVM) has issued multiple warning letters to companies making unsubstantiated therapeutic claims about CBD products for companion animals. Because CBD pet products are marketed as dietary supplements rather than new animal drugs, they bypass pre-market safety and efficacy review, bioequivalence testing, and Good Manufacturing Practice (GMP) compliance requirements that govern veterinary pharmaceuticals.
2018 Farm Bill descheduling and its limits
The 2018 Agriculture Improvement Act descheduled hemp and hemp-derived compounds from the Controlled Substances Act but did not independently authorize inclusion of CBD in food, dietary supplements, or animal products without separate regulatory approval. Individual states have enacted divergent regulatory frameworks — some permitting CBD in animal products under state-level oversight, others imposing restrictions or prohibitions. Veterinary practice law also varies by jurisdiction, with some state boards permitting veterinarians to discuss CBD with clients while others maintain more restrictive professional conduct guidelines.
Third-party analytical testing (COA)
The practical consequence of the regulatory gap is that no federal agency currently verifies that a given CBD pet product contains the cannabidiol concentration stated on its label, is free from contaminants, or delivers any clinically meaningful therapeutic effect. Independent laboratory analyses have found products containing significantly less cannabidiol than label claims, others harboring heavy metal or pesticide contaminants, and a subset presenting detectable THC concentrations exceeding stated amounts. A Certificate of Analysis (COA) from an ISO 17025–accredited third-party laboratory is the primary available quality assurance mechanism. A legitimate COA should verify cannabidiol concentration against label claims, confirm delta-9-THC remains below the 0.3% legal threshold, and provide contaminant screening for heavy metals, pesticide residues, mycotoxins, and residual extraction solvents.
Extract classification: whole-plant, THC-removed, isolate
Whole-plant extracts retain the native phytocannabinoid profile (including minor cannabinoids CBG, CBN, CBC) along with trace THC within the 0.3% legal threshold. THC-removed formulations undergo additional processing to remove detectable THC while preserving other cannabinoid and terpene constituents. Isolate is crystalline-pure CBD (>99% cannabidiol) stripped of all other plant compounds. The "entourage effect" hypothesis — positing that whole-plant preparations achieve superior therapeutic outcomes through synergistic cannabinoid-terpene interactions — has not been conclusively demonstrated in canine models, though it draws mechanistic support from in vitro and rodent data.
Key takeaway
The FDA has not approved CBD for veterinary use. CBD pet products are sold as dietary supplements without pre-market safety or efficacy review. Third-party COA verification is the primary quality assurance mechanism available to practitioners and researchers evaluating specific products.
Comparative evidence: CBD vs. alternative supplements
The limitations of the CBD behavioral evidence base — small sample sizes, CYP450 interaction profile, regulatory ambiguity, and the critical finding that CBD monotherapy failed to reach significance in the most recent crossover trial — motivate review of alternative supplement categories with distinct pharmacological mechanisms.
Amino acid and peptide blends
Product-specific evidence; some canine RCT data available. Avoids CYP450 interaction profile.
Formulations containing L-theanine (a glutamate analog modulating GABAergic neurotransmission), L-tryptophan (the rate-limiting precursor in the tryptophan-hydroxylase pathway to serotonin synthesis), or alpha-casozepine (a bovine alpha-S1-casein–derived decapeptide with reported GABA-A receptor affinity) each have published canine studies. Scandurra, Mastellone, Pero, and colleagues (2022; PMCID: PMC8868118) conducted an RCT enrolling 21 dogs in a 30-day double-blind placebo-controlled design testing DìRelax, a blend of krill oil, California poppy, hops, ashwagandha, passionflower, vitamin B6, and vitamin E. The treated group reached the solvable task phase sooner; 6 of 42 C-BARQ items showed improvement. Evidence quality is product-specific rather than class-wide. Critically, the Flint et al. (2025) arm combining CBD 2 mg/kg with L-tryptophan and alpha-casozepine was the only arm to reach significance (p=0.016), suggesting these amino acid and peptide constituents may contribute meaningfully to multi-ingredient formulation efficacy.
Gut-brain axis (probiotics)
Mechanistically plausible; canine behavioral evidence remains preliminary.
Sacoor, Marugg, Empadinhas, and Montezinho (2024; PMCID: PMC10827376) published a narrative review synthesizing rodent, human, and dog studies on microbiome–gut-brain axis signaling, including vagus-nerve communication, microbial metabolites, and hypothalamic-pituitary-adrenal axis regulation. The review concludes that probiotic evidence for behavioral anxiolysis in dogs remains preliminary, with this intervention positioned as mechanistically plausible but insufficiently validated in canine behavioral applications. This category circumvents cannabinoid-related regulatory and pharmacokinetic concerns.
Behavioral and environmental interventions
Non-supplement approaches with separate evidence bases.
Pressure wraps (providing sustained proprioceptive input theorized to activate the parasympathetic nervous system), synthetic pheromone analogs (mimicking dog-appeasing pheromone from nursing dams), environmental enrichment protocols, and structured behavior modification programs employing systematic desensitization and counterconditioning represent non-supplement intervention strategies. The literature consistently positions nutraceutical interventions as adjuncts to, rather than substitutes for, behavioral modification — particularly for separation-related and generalized anxiety phenotypes. The calming supplements guide provides the full ingredient-class analysis.
Key takeaway
The Flint et al. (2025) finding that only the CBD, L-tryptophan, and alpha-casozepine arm reached significance, while CBD monotherapy did not, suggests the amino acid and peptide constituents contribute meaningfully to multi-ingredient formulation outcomes. Alternative categories — amino acid blends, probiotics, and behavioral modification — have their own evidence profiles and avoid the CYP450 interaction and regulatory constraints associated with cannabinoid products.
How this guide connects to the Pawsd knowledge base
Pawsd keeps this CBD evidence review in its canine-anxiety reference set. Scout uses its safety limits, study gaps, and product-quality cautions when answering CBD questions for individual dogs. The page is revised when new peer-reviewed veterinary evidence changes that risk-benefit picture.
Frequently asked questions
What does current research conclude about CBD monotherapy for canine anxiety?
As of 2025, CBD monotherapy has not demonstrated significant anxiolytic efficacy in the most rigorous crossover trial conducted to date. Flint, Weller, Hunt, and King (2025; PMCID: PMC12339541) enrolled 54 dogs in a blinded 4-arm crossover, testing placebo, CBD 2 mg/kg, CBD 4 mg/kg, and a combination treat. CBD alone at neither dose reached significance for cortisol attenuation. Only the CBD 2 mg/kg, L-tryptophan, and alpha-casozepine treat reached significance (p=0.016). The 2023 Di Salvo review (PMCID: PMC10347378) identified only three clinical behavioral studies in dogs prior to that trial, with results spanning the full range from negative to positive.
What did the Hunt et al. behavioral study actually find?
Hunt and colleagues (2023; PMCID: PMC9992179) found that Quantitative Behavioral Analysis (QBA) measures — specifically stress, tension, discomfort, sadness, and whining — did reach statistical significance and showed improvement in the CBD condition during acute separation and car-travel stressors. This is a genuine positive finding for those behavioral endpoints. The authors cautioned against generalizing these formulation-specific results to CBD products as a commercial category, given that bioavailability, formulation excipients, and cannabinoid concentration vary substantially across products.
How does CBD interact with common canine medications?
CBD primarily inhibits CYP450 enzymes, which are responsible for metabolizing a wide range of co-administered pharmaceuticals. Dogs receiving anticonvulsants (phenobarbital, potassium bromide, zonisamide), NSAIDs, or other CYP450-metabolized drugs face elevated risk of pharmacokinetic interactions. Dose-dependent hepatic ALP elevation has also been documented across multiple canine CBD studies, as summarized by Di Salvo et al. (2023; PMCID: PMC10347378), warranting baseline and serial hepatic monitoring in dogs with pre-existing hepatobiliary disease.
Why is CBD hemp different from hemp-seed products?
Hemp seeds contain negligible concentrations of cannabidiol or other pharmacologically active cannabinoids; CBD is synthesized in the inflorescences and leaves, not the seeds. A product labeled "hemp calming chew" that does not specify cannabidiol content in milligrams per serving is likely a hemp-seed derivative with no meaningful CBD activity — though labels reading "hemp extract," "whole-plant extract," or "THC-removed extract" may still contain cannabinoids and require COA verification. The two product types occupy different regulatory classifications, present different phytochemical profiles, and carry different clinical relevance for anxiolytic applications.
What is the regulatory status of CBD in veterinary products?
The FDA has not approved, conditionally approved, or indexed any CBD product for veterinary use. The 2018 Agriculture Improvement Act descheduled hemp-derived CBD from the Controlled Substances Act but did not authorize its inclusion in dietary supplements or food without separate FDA approval. CBD pet products are sold as dietary supplements, bypassing pre-market safety and efficacy review. State regulatory frameworks vary, and veterinary practice law differs by jurisdiction. The operative federal THC threshold is not more than 0.3 percent delta-9 THC on a dry weight basis.
Evidence-informed article
Pawsd Knowledge articles are educational and not a substitute for veterinary advice. These pages draw from selected open-access peer-reviewed veterinary research, with full-text sources linked below.
Selected references
Di Salvo A, Conti MB, della Rocca G. Front Vet Sci. 2023;10:1204526. PMCID: PMC10347378. Open-access narrative review.
Front Vet Sci. 2023;10:1248417. PMCID: PMC10540436. Open-access systematic review/meta-analysis.
Hunt ABG, Flint HE, Logan DW, King T. Front Vet Sci. 2023;10:1112604. PMCID: PMC9992179. Open-access placebo-controlled study.
Flint HE, Weller JE, Hunt ABG, King T. Front Vet Sci. 2025;12:1632868. PMCID: PMC12339541. Open-access blinded 4-arm crossover (n=54).
Sacoor C, Marugg JD, Empadinhas N, Montezinho L. Vet Med Int. 2024;2024:2856759. PMCID: PMC10827376. Open-access narrative review.
Rideout H, Cook AJC, Whetton AD, et al. J Cannabis Res. 2025;7(1):6. PMCID: PMC11755934. Open-access review of CBD quality assurance and regulatory context for veterinary products.
Related Reading
Acepromazine for Dog Anxiety: Sedation, Fear, and Modern Vet Use
A veterinary-boundary guide to acepromazine for dog anxiety questions, explaining sedation without anxiety relief, noise-fear concerns, historical use, monitoring issues, and modern alternatives.
Dog-Appeasing Pheromone (DAP): Efficacy and Evidence Review
An evidence-based review of dog-appeasing pheromone (DAP) efficacy, vomeronasal processing mechanisms, and clinical limitations in canine behavioral therapy.
Alpha-Casozepine for Dogs: Calming Supplement Evidence and Limits
An evidence-reference guide to alpha-casozepine for dogs, covering proposed GABA-A mechanisms, calming-supplement use, canine evidence limits, combination-product caveats, and when prescription care is more appropriate.
The First Week After Adopting a Dog: Physiological and Behavioral Adjustment
Shelter dogs arrive with elevated physiological stress markers that require time to down-regulate. This guide examines what the research shows about the adjustment arc in newly adopted dogs: the physiological baseline at adoption, the 3-3-3 framework for behavioral adjustment, how schedule predictability reduces arousal, the case for introducing alone time early, and what adopter expectation surveys document about the gap between expected and experienced outcomes.
© 2026 Pawsd LLC. All rights reserved. The selection, arrangement, and original commentary in this guide are the copyrighted work of Pawsd. While the underlying research is publicly available, the editorial analysis, evidence curation, and breed-specific guidance reflect original work. Reproduction or redistribution of this material without written permission is prohibited. For licensing inquiries, contact hello@pawsd.ai.